Reference
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J
Clin. 2020 Jan;70(1):7-30.
2. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M,
et al. Survival and recurrence after concomitant chemotherapy and
radiotherapy for cancer of the uterine cervix: a systematic review and
meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6.
3. Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic
factors for patients with cervical cancer treated with concurrent
chemoradiotherapy: a retrospective analysis in a Japanese cohort. J
Gynecol Oncol. 2015 Jan;26(1):12-8.
4. Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing
uncertainties about the effects of chemoradiotherapy for cervical
cancer: a systematic review and meta-analysis of individual patient data
from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12.
5. Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, et al. The Prognosis
and Risk Stratification Based on Pelvic Lymph Node Characteristics in
Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated
With Concurrent Chemoradiotherapy. Int J Gynecol Cancer. 2016
Oct;26(8):1472-9.
6. Chen CC, Wang L, Lin JC, Jan JS. The prognostic factors for locally
advanced cervical cancer patients treated by intensity-modulated
radiation therapy with concurrent chemotherapy. J Formos Med Assoc. 2015
Mar;114(3):231-7.
7. Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, et al. Concurrent
chemoradiotherapy incorporating high-dose rate brachytherapy for locally
advanced cervical carcinoma: survival outcomes, patterns of failure, and
prognostic factors. Int J Gynecol Cancer. 2010 Apr;20(3):428-33.
8. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front
Oncol. 2013;3:34.
9. Guo F, Yang R, Tian J, Fan L. The role of F-fluorodeoxyglucose (FDG)
positron emission tomography-computed tomography (PET/CT) in the
screening of cervical cancer: a literature review. Cell Biochem Biophys.
2014 Jun;69(2):197-201.
10. N G, MA A, WE P, AG R, TD B. - FDG-PET Imaging in Cervical Cancer. D
- 1264464. (- 1558-4623 (Electronic)):- 461-70.
11. Im HJ, Yoon HJ, Lee ES, Kim TS, Kim JY, Chung JK, et al. Prognostic
implication of retrocrural lymph node involvement revealed by (18)F-FDG
PET/CT in patients with uterine cervical cancer. Nucl Med Commun. 2014
Mar;35(3):268-75.
12. Chong GO, Jeong SY, Park SH, Lee YH, Lee SW, Hong DG, et al.
Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of
Primary Tumors and Regional Lymph Nodes in Patients with Locally
Advanced Cervical Cancer Who Are Treated with Concurrent
Chemoradiotherapy. PLoS One. 2015;10(9):e0137743.
13. Akkus Yildirim B, Onal C, Erbay G, Cem Guler O, Karadeli E, Reyhan
M, et al. Prognostic values of ADCmean and SUVmax of the primary tumour
in cervical cancer patients treated with definitive chemoradiotherapy. J
Obstet Gynaecol. 2019 Feb;39(2):224-30.
14. Cima S, Perrone AM, Castellucci P, Macchia G, Buwenge M, Cammelli S,
et al. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron
Emission Tomography/Computed Tomography SUVmax in Patients With Locally
Advanced Cervical Cancer. Int J Gynecol Cancer. 2018 Mar;28(3):575-80.
15. Guler OC, Torun N, Yildirim BA, Onal C. Pretreatment metabolic
tumour volume and total lesion glycolysis are not independent
prognosticators for locally advanced cervical cancer patients treated
with chemoradiotherapy. Br J Radiol. 2018 Apr;91(1084):20170552.
16. Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P,
et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI
radiomics in locally advanced cervical cancer treated with
chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018 May;45(5):768-86.
17. Hong JH, Jung US, Min KJ, Lee JK, Kim S, Eo JS. Prognostic value of
total lesion glycolysis measured by 18F-FDG PET/CT in patients with
locally advanced cervical cancer. Nucl Med Commun. 2016 Aug;37(8):843-8.
18. Onal C, Reyhan M, Parlak C, Guler OC, Oymak E. Prognostic value of
pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical
cancer treated with definitive chemoradiotherapy. Int J Gynecol Cancer.
2013 Jul;23(6):1104-10.
19. Lee WK, Chong GO, Jeong SY, Lee HJ, Park SH, Ryu JM, et al.
Prognosis-Predicting Model Based on [(18)F]fluorodeoxyglucose PET
Metabolic Parameters in Locally Advanced Cervical Cancer Patients
Treated with Concurrent Chemoradiotherapy: Multi-Center Retrospective
Study. J Clin Med. 2020 Feb 5;9(2).
20. Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M.
[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors
in cervical cancer patients treated with chemo-radiotherapy. Radiat
Oncol. 2016 Mar 16;11:43.
21. Yilmaz B, Dag S, Ergul N, Cermik TF. The efficacy of pretreatment
and after treatment 18F-FDG PET/CT metabolic parameters in patients with
locally advanced squamous cell cervical cancer. Nucl Med Commun. 2019
Mar;40(3):219-27.
22. Onal C, Guler OC, Reyhan M, Yapar AF. Prognostic value of
18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with
cervical cancer treated with definitive chemoradiotherapy. Gynecol
Oncol. 2015 Apr;137(1):40-6.
23. Chong GO, Lee WK, Jeong SY, Park SH, Lee YH, Lee SW, et al.
Prognostic value of intratumoral metabolic heterogeneity on F-18
fluorodeoxyglucose positron emission tomography/computed tomography in
locally advanced cervical cancer patients treated with concurrent
chemoradiotherapy. Oncotarget. 2017 Oct 27;8(52):90402-12.
24. Scher N, Castelli J, Depeursinge A, Bourhis J, Prior JO, Herrera FG,
et al. ((18)F)-FDG PET/CT parameters to predict survival and recurrence
in patients with locally advanced cervical cancer treated with
chemoradiotherapy. Cancer Radiother. 2018 May;22(3):229-35.
25. Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech
Y, et al. Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM
PET/CT. Clin Nucl Med. 2012 Nov;37(11):1065-8.
26. Carpenter DJ, Jacobs CD, Wong TZ, Craciunescu O, Chino JP. Changes
on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission
Tomography for Cervical Cancer Are Associated with Prognosis. Int J
Radiat Oncol Biol Phys. 2019 Oct 1;105(2):356-66.
27. Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM,
Royuela A, Garcia-Espantaleon Navas M, Herrero Gamiz S, et al.
Prognostic significance of metabolic tumor volume and total lesion
glycolysis in patients with advanced cervical carcinoma. Rev Esp Med
Nucl Imagen Mol. 2019 Jan - Feb;38(1):17-21.
28. Liu FY, Lai CH, Yang LY, Wang CC, Lin G, Chang CJ, et al. Utility of
(18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of
the uterine cervix receiving concurrent chemoradiotherapy: a parallel
study of a prospective randomized trial. Eur J Nucl Med Mol Imaging.
2016 Sep;43(10):1812-23.
29. Krhili S, Muratet JP, Roche S, Pointreau Y, Yossi S, Septans AL, et
al. Use of Metabolic Parameters as Prognostic Factors During Concomitant
Chemoradiotherapy for Locally Advanced Cervical Cancer. Am J Clin Oncol.
2017 Jun;40(3):250-5.
30. Park JJ, Kim CK, Park BK. Prognostic value of diffusion-weighted
magnetic resonance imaging and (18)F-fluorodeoxyglucose-positron
emission tomography/computed tomography after concurrent
chemoradiotherapy in uterine cervical cancer. Radiother Oncol. 2016
Sep;120(3):507-11.
31. Oh D, Lee JE, Huh SJ, Park W, Nam H, Choi JY, et al. Prognostic
significance of tumor response as assessed by sequential
18F-fluorodeoxyglucose-positron emission tomography/computed tomography
during concurrent chemoradiation therapy for cervical cancer. Int J
Radiat Oncol Biol Phys. 2013 Nov 1;87(3):549-54.
32. Hong CM, Park SH, Chong GO, Lee YH, Jeong JH, Lee SW, et al.
Enhancing prognosis prediction using pre-treatment nodal SUVmax and HPV
status in cervical squamous cell carcinoma. Cancer Imaging. 2019 Jun
24;19(1):43.